Upgrade Now

Company Announcements

Final Results

Related Companies

RNS Number : 6339R
Taihua Plc
30 June 2015
 



 

Taihua plc

("Taihua" or the "Company")

 

Final Results for the year ended 31 December 2014

 

 

Chairman's Statement

 

Despite not increasing turnover we managed to double our 2013 Profit before Tax. The main reasons for this were the increased importance of relatively high margin Forsythia and a reduction in the level of inventory provisioning.

 


FY2014

FY2013

Sales

RMB 50.9m

RMB 52.3m

Profit before Tax

RMB 6.6m

RMB 3.3m

 

Segmental Sales Analysis (in RMB) 

 


2014

2013

2012

Forsythia

41.8m

41.8m

27.2m

TCMs

 4.9m

 5.7m

6.5m

APIs

 4.2m

 4.8m

5.5m

Total

50.9m

52.3m

39.2m

  

Forsythia

 

Despite the tonnage sold in 2014 falling to 1,146 tonnes (2013: 1,529 tonnes) the revenue generated from this product was the same as 2013. The reason was that the wholesale market reacted to the reduced harvest and the price correspondingly increased. The average selling price in 2014 was RMB 37.8/kg (2013: RMB 28.3/kg) excluding sales tax.

 

Recognising the issues that the forsythia plantations have in terms of the impact of adverse weather conditions we are working with various parties to introduce new cultivation practices and new strains of forsythia to mitigate the effect of poor weather in the future.

 

Finished Product TCMs

 

Sales of Finished Product TCMs fell for the third consecutive year. The distributors remain very cautious regarding taking on new products following the Chinese Government's tightening of GMP legislation and enforcement.

 

Bian Tong Pian sales were RMB 2.6m (2013: RMB 3.6m). Box sales were 191,600 in 2014 (2013: 243,900). The lower sales revenue was reflective of a reduction in selling price from RMB 14.8 per box in 2013 to RMB 13.3 per box in 2014. Bian Tong Pian is distributed in Beijing metropolitan district and Guangzhou military hospitals. It is also approved for sale in six further provinces. In provinces where Taihua has approval to sell but, as yet, no distribution agreements, prospective distributors continue to take small quantities to test the market.

 

APIs

Having temporarily ceased production of Paclitaxel some of our customers have asked us to recommence production. As such we have started production again in 2015, albeit at a lower level than in previous years.

 

Homoharringtonine sales continued at a similar level to the previous year. This product has historically been the most lucrative for Taihua so we are reluctant to exit the sale of this product despite significant inventory obsolescence issues. We remain of the opinion that after GMP reaccreditation we will be able to significantly recover lost Homoharringtonine sales.

 

Balance Sheet

 

Cash and cash equivalent increased to RMB 46.9m from RMB 34.5m. In addition to the improved profitability, the main reason was the reduced level of trade debtors, from RMB 58.0m to RMB 54.7m.

 

The Board of Directors would like to place on record their appreciation of investors' interest in Taihua. Whilst the forsythia business has not been as profitable as was hoped at the outset, the transition from dependence on APIs is largely complete.

 

Annual General Meeting

 

The Company confirms that its AGM will be held on 6 August 2015 at 11am London time at the office of Dentons UKMEA LLP, One Fleet Place, London, EC4M 7WS and that the annual report and accounts will be available from the Company's website www.taihplc.com from that date.

 

Nicholas Lyth

Chairman

 

29 June 2015

 

ENDS

 

 

Enquiries:

 

Nicholas Lyth, Taihua plc                                                              0776 990 6686

 

Katy Mitchell, WH Ireland Limited                                           +44 161 832 2174

 

 

 

 

 

 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 DECEMBER 2014

 

 




2014


2013


    



RMB'000


RMB'000









Revenue



50,948


52,302









Cost of sales  



(37,336)


(41,615)









Gross profit



13,612


10,687









Gain/(Loss) arising on revaluation of biological assets



388


1,077









Other revenue



1,728


2,105









Selling expenses



(6,118)


(6,338)









General and administrative expenses



(3,026)


(4,229)









Profit before income tax



6,584


3,302









Income tax expense



(2,082)


(1,212)









Profit for the year



4,502


2,090









Other comprehensive income :-














Items that may be classified subsequently to profit or loss :-














Exchange differences arising on translation of

  financial statements of foreign operations



 

473


 

98









Other comprehensive income for the year



473


98









Total comprehensive income for the year



4,975


2,188









Profit attributable to :














Equity holders of the parent company



4,502


2,090









Total comprehensive income attributable to :














      Equity holders of the parent company



4,975


2,188









Earnings per share :














      Basic (RMB per share)



0.055


0.026









      Diluted (RMB per share)



0.055


0.026


 

 

 

 

 

 

STATEMENTS OF FINANCIAL POSITION

AS AT 31 DECEMBER 2014

 

 

 

 

2014

 

2013

 

 

 

 

RMB'000

 

RMB'000

 

Non-current assets

 

 

 

 

 

 

Property, plant and equipment

 

 

2,575

 

2,046

 

Prepaid lease payments

 

 

50,500

 

53,450

 

Land use rights

 

 

1,369

 

1,408

 

Biological assets

 

 

4,387

 

4,563

 

Intangible assets

 

 

-

 

-

 

          Deferred tax assets

 

 

306

 

-

 

 

 

 

59,137

 

61,467

 

Current assets

 

 

 

 

 

 

Inventories

 

 

10,592

 

9,920

 

Trade receivables

 

 

54,722

 

58,039

 

Other receivables

 

 

465

 

714

 

Deposits and prepayments

 

 

2,715

 

2,791

 

Cash and cash equivalents  

 

 

46,876

 

34,512

 

 

 

 

115,370

 

105,976

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

 

174,507

 

167,443

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Trade payables

 

 

1,281

 

2,236

 

Receipts in advance

 

 

987

 

182

 

Accrued expenses and other payables

 

 

15,814

 

14,722

 

Amounts due to related companies

 

 

1,107

 

1,148

 

Amount due to a shareholder

 

 

8,001

 

605

 

Amounts due to directors

 

 

26

 

6,721

 

Income tax payable

 

 

2,669

 

1,961

 

 

 

 

29,885

 

27,575

 

 

 

 

 

 

 

 

Net current assets

 

 

85,485

 

78,401

 

 

 

 

 

 

 

 

Non-current liability

 

 

 

 

 

 

          Deferred tax liability

 

 

-

 

221

 

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

 

29,885

 

27,796

 

 

 

 

 

 

 

 

NET ASSETS

 

 

144,622

 

139,647

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

 

 

Capital and reserves attributable to

 

 

 

 

 

 

Equity holders of the company

 

 

 

 

 

 

Share capital

 

 

12,357

 

12,357

 

Other reserves

 

 

19,621

 

19,148

 

Retained profits

 

 

112,644

 

108,142

 

 

 

 

 

 

 

 

TOTAL EQUITY 

 

 

144,622

 

139,647

 

 

The financial statements were approved and authorised for issue by the Board of Directors on 29 June 2015.


CONSOLIDATED STATEMENT OF CHANGES in EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2014

 

 














Foreign











Merger




Reverse


General


Enterprise


currency


Share







Share


relief


Share


acquisition


reserve


expansion


translation


options


Retained





capital


reserve


premium


reserve


fund


fund


reserve


reserve


profits


Total



RMB'000


RMB'000


RMB'000


RMB'000


RMB'000


RMB'000


RMB'000


RMB'000


RMB'000


RMB'000























At 1 January 2013

12,357


64,364


4,783


(63,408)


9,297


4,648


(1,128)


494


106,052


137,459























Profit for the year

-


-


-


-


-


-


-


-


2,090


2,090


Other comprehensive income

-


-


-


-


-


-


98


-


-


98























Total comprehensive income





















  for the year

-


-


-


-


-


-


98


-


2,090


2,188























At 31 December 2013

12,357


64,364


4,783


(63,408)


9,297


4,648


(1,030)


494


108,142


139,647























At 1 January 2014

12,357


64,364


4,783


(63,408)


9,297


4,648


(1,030)


494


108,142


139,647























Profit for the year

-


-


-


-


-


-


-


-


4,502


4,502


Other comprehensive income

-


-


-


-


-


-


473


-


-


473























Total comprehensive income





















  for the year

-


-


-


-


-


-


473


-


4,502


4,975























At 31 December 2014

12,357


64,364


4,783


(63,408)


9,297


4,648


(557)


494


112,644


144,622



CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2014

 

 


2014


2013



RMB'000


RMB'000


Cash flows from operating activities





      Operating profit

6,584


3,302


      Adjustments for :-





             Increase/(reversal) in allowance for bad debts

(188)


1,051


             Amortisation of prepaid lease payments

2,950


2,950


             Amortisation of land use rights

39


38


             Depreciation

261


261


             Loss/(gain) arising on revaluation of biological assets

(388)


(487)


             Change in fair value of harvested products

564


(590)


             Interest income

(1,540)


(2,105)


             Increase/(decrease) in allowance for write-down of inventories

1,908


1,939


      Operating cash flows before working capital changes

10,190


6,359







             Decrease/(increase) in inventories

(2,580)


2,992


             Decrease/(increase) in trade receivables

3,520


(18,544)


             Decrease/(increase) in other receivables

234


(389)


             Decrease/(increase) in deposits and prepayments

76


874


             Increase/(decrease) in trade payables

(955)


1,665


             Increase/(decrease) in receipts in advance  

805


(316)


             Increase/(decrease) in accrued expenses and other payables

1,051


2,088


             Increase/(decrease) in amount due to a shareholder

701


(7)


             Increase/(decrease) in amounts due to directors

-


(87)


      Cash generated from/(used in) operations

13,042


(5,365)







      Interest received

1,540


2,105


      Profits tax paid

(1,901)


(1,598)







Net cash from/(used in) operating activities

12,681


(4,858)







Cash flows from investing activity





      Purchase of property, plant and equipment

(790)


(66)







Net cash used in investing activity    

(790)


(66)












Net increase/(decrease) in cash and cash equivalents

11,891


(4,924)







Cash and cash equivalents as at 1 January

34,512


39,338







Effect of foreign exchange change  

473


98







Cash and cash equivalents as at 31 December

46,876


34,512


Analysis of the balances of cash and cash equivalents





      Cash and bank balances

46,876


34,512


 

 

 

 

 

Notes

 

1.            GENERAL INFORMATION

 

Taihua Plc (the "Company") was incorporated and registered in England and Wales on 29 August 2006 under the Companies Act 1985 as a public company limited by shares with the name "China Natural plc" with registered number 05918155. On 8 September 2006, the Company changed its name to "Taihua plc". The address of the registered office is 4th Floor, Capital House, 85 King William Street, London, EC4N 7BL, and the principal place of business is Room 201, Unit 3, No. 16 Zhong Hua, ShiJiCheng, FuZeYuan, 239 KeJi Road, Hi-tech Zone, Xi An, 710077, People's Republic of China (the "PRC").

 

The Company is an investment holding company and its subsidiaries are principally engaged in the manufacturing and sales of pharmaceutical products.  The consolidated financial statements are presented in Renminbi ("RMB"), the currency of the primary economic environment in which the trading company operates.

 

2.            EARNINGS PER SHARE

 

Basic earnings per share

 

Basic earnings per share is calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the year.

 

 

Diluted earnings per share

 

The Company has only one category of dilutive potential shares - share options. A calculation is done to determine the number of shares that could have been acquired at fair value based on the monetary value of the subscription rights attached to outstanding share options. It is compared with the number of shares that would have been issued assuming the exercise of the share options.

 




2014


     2013


       Profit attributable to equity holders of the






              Company (RMB'000)


4,502


2,090









       Weighted average number of ordinary shares






              in issue (thousands)


81,737


81,737


       Adjustment for share options (thousands)


-


-









       Weighted average number of ordinary shares






              for diluted earnings (thousands)


81,737


81,737









       Diluted earnings per share (RMB per share)


0.055


0.026


 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR SDASWSFISEIM

Top of Page